Welcome to our dedicated page for Pacific Software news (Ticker: PFSF), a resource for investors and traders seeking the latest updates and insights on Pacific Software stock.
Pacific Software Inc. reports company developments tied to its completed acquisition of PurMinds NeuroPharma, an OTC-quoted public-company platform focused on precision neuromedicine. News coverage centers on material agreements, capital-structure updates, and product-development themes involving neurological and psychiatric disorders, point-of-care diagnostic solutions, clinical biomarker validation, and therapeutics designed around neuroplasticity and neuroinflammation.
Company announcements also document earlier activity in science-based skin care, wound-healing technology, and memory-health products, including Dermatrix, peptide IDE inhibitor licensing, and the SuppleMEM AD and A.L.Z. Defense supplement brands.
Pacific Software, Inc. (OTC PINK:PFSF) announced a debt restructuring of approximately $3,000,000 to enhance its capital structure ahead of its growth initiatives for 2022. The restructuring moves legacy notes from a fixed percentage to a fixed price conversion rate, eliminating liability premiums and interest expenses. This adjustment is expected to simplify accounting and improve financial transparency. The company aims to launch several new restaurant locations and brands soon, indicating a robust growth strategy.
Pacific Software, Inc. (OTCPINK:PFSF) is repositioning to enter the fast casual restaurant market, projected to grow from $125.6 billion in 2019 to $209.1 billion by 2027, at a CAGR of 10.6%.
To spearhead this transition, the company has appointed Isaac Onn as CEO and Michael Finkelstein as COO, both with extensive industry experience. Their strategy includes acquiring restaurant chains affected by the Covid-19 pandemic, aiming to build a diverse cash flow portfolio. The company will also undergo a name change and is launching a new website soon.